Understanding pulmonary hypertension: the need for an integrative metabolomics and transcriptomics approach

IF 3 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular omics Pub Date : 2024-05-21 DOI:10.1039/D3MO00266G

Priyanka Choudhury, Sanjukta Dasgupta, Parthasarathi Bhattacharyya, Sushmita Roychowdhury and Koel Chaudhury

{"title":"Understanding pulmonary hypertension: the need for an integrative metabolomics and transcriptomics approach","authors":"Priyanka Choudhury, Sanjukta Dasgupta, Parthasarathi Bhattacharyya, Sushmita Roychowdhury and Koel Chaudhury","doi":"10.1039/D3MO00266G","DOIUrl":null,"url":null,"abstract":"<p >Pulmonary hypertension (PH), characterised by mean pulmonary arterial pressure (mPAP) >20 mm Hg at rest, is a complex pathophysiological disorder associated with multiple clinical conditions. The high prevalence of the disease along with increased mortality and morbidity makes it a global health burden. Despite major advances in understanding the disease pathophysiology, much of the underlying complex molecular mechanism remains to be elucidated. Lack of a robust diagnostic test and specific therapeutic targets also poses major challenges. This review provides a comprehensive update on the dysregulated pathways and promising candidate markers identified in PH patients using the transcriptomics and metabolomics approach. The review also highlights the need of using an integrative multi-omics approach for obtaining insight into the disease at a molecular level. The integrative multi-omics/pan-omics approach envisaged to help in bridging the gap from genotype to phenotype is outlined. Finally, the challenges commonly encountered while conducting omics-driven studies are also discussed.</p>","PeriodicalId":19065,"journal":{"name":"Molecular omics","volume":" 6","pages":" 366-389"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular omics","FirstCategoryId":"99","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/mo/d3mo00266g","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pulmonary hypertension (PH), characterised by mean pulmonary arterial pressure (mPAP) >20 mm Hg at rest, is a complex pathophysiological disorder associated with multiple clinical conditions. The high prevalence of the disease along with increased mortality and morbidity makes it a global health burden. Despite major advances in understanding the disease pathophysiology, much of the underlying complex molecular mechanism remains to be elucidated. Lack of a robust diagnostic test and specific therapeutic targets also poses major challenges. This review provides a comprehensive update on the dysregulated pathways and promising candidate markers identified in PH patients using the transcriptomics and metabolomics approach. The review also highlights the need of using an integrative multi-omics approach for obtaining insight into the disease at a molecular level. The integrative multi-omics/pan-omics approach envisaged to help in bridging the gap from genotype to phenotype is outlined. Finally, the challenges commonly encountered while conducting omics-driven studies are also discussed.

Abstract Image

查看原文本刊更多论文

了解肺动脉高压：需要综合代谢组学和转录组学方法

肺动脉高压（PH）的特点是静息时平均肺动脉压（mPAP）为 20 mmHg，是一种与多种临床症状相关的复杂病理生理紊乱。该病发病率高，死亡率和发病率增加，成为全球健康负担。尽管在了解该疾病的病理生理学方面取得了重大进展，但许多潜在的复杂分子机制仍有待阐明。缺乏可靠的诊断测试和特定的治疗靶点也构成了重大挑战。本综述利用转录组学和代谢组学方法全面更新了 PH 患者体内失调的通路和有希望的候选标记物。该综述还强调了使用综合多组学方法从分子水平深入了解疾病的必要性。此外，还概述了有助于弥合从基因型到表型之间差距的综合性多组学/泛组学方法。最后，还讨论了在进行组学驱动的研究时通常会遇到的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular omics Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

5.40

自引率

3.40%

发文量

期刊介绍： Molecular Omics publishes high-quality research from across the -omics sciences. Topics include, but are not limited to: -omics studies to gain mechanistic insight into biological processes – for example, determining the mode of action of a drug or the basis of a particular phenotype, such as drought tolerance -omics studies for clinical applications with validation, such as finding biomarkers for diagnostics or potential new drug targets -omics studies looking at the sub-cellular make-up of cells – for example, the subcellular localisation of certain proteins or post-translational modifications or new imaging techniques -studies presenting new methods and tools to support omics studies, including new spectroscopic/chromatographic techniques, chip-based/array technologies and new classification/data analysis techniques. New methods should be proven and demonstrate an advance in the field. Molecular Omics only accepts articles of high importance and interest that provide significant new insight into important chemical or biological problems. This could be fundamental research that significantly increases understanding or research that demonstrates clear functional benefits. Papers reporting new results that could be routinely predicted, do not show a significant improvement over known research, or are of interest only to the specialist in the area are not suitable for publication in Molecular Omics.